Abbvie submits all-oral hep C application to U.S. regulators; Kala's eye delivery platform spurs $22.5M funding round;

> Abbvie ($ABBV) submitted an FDA application for its all-oral hepatitis C treatment. Story

> Kala Pharmaceuticals, co-founded by Robert Langer, closed a $22.5 million funding round, looking to push forward its ocular treatments that use the company's mucus-penetrating particle delivery platform. Article

> Nitto Denko completed dose escalation of its Phase Ia RNAi-based treatment for fibrosis in the liver and other organs. The siRNA is delivered with a lipid nanoparticle delivery system the company developed in collaboration with Yoshiro Niitsu of Sapporo Medical University. Release

> Ocular Therapeutix will present Phase II data regarding its ReSure Sealant hydrogel with sustained-release dexamethasone at the upcoming American Society of Cataract and Refractive Surgery annual symposium in Boston. Release

> Researchers at the University of Kentucky have developed a method to create heat-resistant nanostructures--including drug delivery structures--using RNA as a building tool. More

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.